Class 4 Medicines Defect Information:
Metronidazole 200 mg/5 ml Oral Suspension (Drugsrus Limited / Dawa Limited)
Drug alert number: EL (23)A/19
Date issued: 23 May 2023
The Medicines and Health products Regulatory Agency (MHRA) has issued a class 4 medicines defect information notice for:
Product name:Metronidazole 200 mg/5 ml Oral Suspension, PL 30684/0236
Batch No
Expiry Date
Pack Size
First Distributed
C20070
03/2025
100ml
11/10/2022
C20071
03/2025
100ml
24/01/2023
C20072
03/2025
100ml
28/12/2022
Active Pharmaceutical Ingredient: metronidazole benzoate
Brief description of the problem
Drugsrus Limited has informed the MHRA that a small number of bottles of Metronidazole 200 mg/5 ml Oral Suspension 100ml are leaking from the cap. The probable root cause for this defect is related to the possibility of a slight defect in the cap or bottle threads. Only the batches listed in this notification are affected. Due to the very low number of complaints received and the high visibility of the defect usually prior to dispensing, the product is not currently being recalled.
Advice for healthcare professionals
Healthcare professionals are advised to check any incoming bottles from the batches listed above for leaks from the cap.
Do not dispense any bottles that are found to be leaking. Quarantine any affected bottles immediately. Contact Drugsrus Limited (see Further Information section) for replacement and further advice.
View full alert here.
Further Information
For more information, medical or supply enquiries, please contact Drugsrus Limited on 020 8423 3800, or email info@drugsrus.co.uk.
The post Class 4 Medicines Defect Information: Metronidazole 200 mg/5 ml Oral Suspension (Drugsrus Limited / Dawa Limited) appeared first on PSNC Website.